Systemic Sclerosis Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Acceleron, Accuitis, AnaMar, arGentis, Bayer, BriaCell

 Breaking News
  • No posts were found

Systemic Sclerosis Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Acceleron, Accuitis, AnaMar, arGentis, Bayer, BriaCell

September 07
23:12 2023
Systemic Sclerosis Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Acceleron, Accuitis, AnaMar, arGentis, Bayer, BriaCell
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 50+ key pharma and biotech companies are working on 50+ pipeline drugs in the Systemic Sclerosis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Systemic Sclerosis Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Systemic Sclerosis Market. 

The Systemic Sclerosis Pipeline report embraces in-depth commercial, regulatory, and Systemic Sclerosis clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Systemic Sclerosis drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Systemic Sclerosis Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Systemic Sclerosis treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Systemic Sclerosis therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major Systemic Sclerosis companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Systemic Sclerosis drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Systemic Sclerosis therapeutic market.

Systemic Sclerosis (SSc) Therapeutics Landscape

No treatment has been proven to modify the overall disease course, but the therapy targets specific organ involvement early before irreversible damage to improve both quality of life and survival. The therapeutic market is driven by the increase in prevalent cases and is mainly driven by the patient pools of 30–50 years. The therapeutic market size is accounted for therapies directed toward the management of specific symptoms, and current therapies use medications that focus on the four main features of the disease: inflammation, autoimmunity, vascular disease, and tissue fibrosis. Currently, immunosuppressive agents such as methotrexate, cyclophosphamide, mycophenolate mofetil, Azathioprine; autologous stem cell transplantation, and others are therapeutic choices for Systemic Sclerosis.

Treatment of Systemic Sclerosis varies according to the manifestation such as cutaneous, pulmonary, gastric, heart, and renal, and most of the therapies aim to treat the specific organ involvement to avoid irreversible damage as well as to improve both qualities of life and survival.

Currently, there are approx. 50+ key companies developing therapies for Systemic Sclerosis to improve the treatment outcome. Currently, Eicos Sciences is leading the therapeutics market with its Systemic Sclerosis drug candidates in the most advanced stage of clinical development.

Systemic Sclerosis Companies Actively Working in the Therapeutic Market Include:

Acceleron Pharma, Accuitis Pharmaceuticals, AKL Research and Development, AnaMar, arGentis Pharmaceuticals, ASKA Pharmaceutical, Atlantic Healthcare, Bayer, Beijing Continent Pharmaceutical, Blade Therapeutics, BriaCell Therapeutics, Bristol-Myers Squibb, Camurus, Cantargia, Castle Creek Biosciences, Certa Therapeutics, Chemomab therapeutics, Corbus Pharmaceuticals, CSL Behring, Cumberland Pharmaceuticals, Cytori therapeutics, D&D Pharmatech, Eicos Sciences, Emerald Health Pharmaceuticals, Formation Biologics, Gesynta Pharma, GlaxoSmithKline, Horizon Pharmaceuticals, Horizon Therapeutics, iBio, ILTOO Pharma, Janssen Biotech, Kadmon Pharmaceuticals, Kyowa Kirin, Leadiant Biosciences, Mitsubishi Tanabe Pharma, Pfizer, Regeneron Pharmaceuticals, Regeneron Pharmaceuticals, Riptide Bioscience, Sanofi, Seagen, Talaris Therapeutics, Timber Pharmaceuticals, Tvardi Therapeutics, United Therapeutics, Vicore Pharma, Viela Bio, Zenyaku Kogyo, and many others.

Emerging and Marketed Systemic Sclerosis Drugs Covered in the Report Include:

  • Iloprost: Eicos Sciences

  • ECCS 50: Cytori therapeutics

  • Lenabasum (JBT-101): Corbus Pharmaceuticals

  • EHP-101: Emerald Health Pharmaceuticals

And many more

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Systemic Sclerosis Companies Working in the Market @


Analysis of Emerging Systemic Sclerosis Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued and inactive candidates

Route of Administration

Systemic Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Learn How the Systemic Sclerosis Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @


Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Systemic Sclerosis Treatment Patterns

4. Systemic Sclerosis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Systemic Sclerosis Late Stage Products (Phase-III)

7. Systemic Sclerosis Mid-Stage Products (Phase-II)

8. Systemic Sclerosis Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Systemic Sclerosis Discontinued Products

13. Systemic Sclerosis Product Profiles

14. Major Systemic Sclerosis Companies in the Market

15. Key Products in the Systemic Sclerosis Therapeutics Segment

16. Dormant and Discontinued Products

17. Systemic Sclerosis Unmet Needs

18. Systemic Sclerosis Future Perspectives

19. Systemic Sclerosis Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

 Eczema Market 

“Eczema Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the  Eczema market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the  Eczema market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Related Articles